Page 3 - Aadi Bioscience News Today

Aadi Bioscience, Inc. (NASDAQ:AADI – Get Free Report) Chairman Neil Desai sold 7,037 shares of the stock in a transaction that occurred on Wednesday, December 6th. The shares were sold at an average price of $4.82, for a total value of $33,918.34. Following the sale, the chairman now owns 1,537,543 shares of the company’s stock, […]

Aadi Bioscience, Inc. (NASDAQ:AADI – Get Free Report) Chairman Neil Desai sold 7,037 shares of the stock in a transaction on Wednesday, December 6th. The shares were sold at an average price of $4.82, for a total value of $33,918.34. Following the completion of the sale, the chairman now owns 1,537,543 shares in the company, […]

Aadi Bioscience, Inc. (NASDAQ:AADI – Get Free Report) Chairman Neil Desai sold 8,347 shares of the business’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $5.14, for a total transaction of $42,903.58. Following the completion of the sale, the chairman now owns 1,571,196 shares in the […]

Apart from the already existing players such as Pfizer, Sanofi, Taiho Pharma, Ono Pharma, along with others, there are several emerging key players, that are...

Operator: Good day, and thank you for standing by. Welcome to the Aadi Bioscience Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.

/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically...

Aadi Bioscience, Inc. (AADI) Wednesday reported loss for the third quarter on higher expenses, wider than the prior year. However, on a per-share basis, loss was narrower than the prior year.

Aadi Bioscience, Inc. (NASDAQ:AADI – Get Free Report) Chairman Neil Desai sold 10,338 shares of the business’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $4.32, for a total transaction of $44,660.16. Following the completion of the transaction, the chairman now owns 1,611,205 shares in the […]

Aadi initiates Phase 2 trial investigating the combination of nab-sirolimus with letrozole for the treatment of advanced or recurrent endometrioid-type endometrial cancer LOS ANGELES, Oct. 19,...

Two new real-world next-generation sequencing studies reinforce prevalence of TSC1/2 mutations in up to 2% of all tumors, a significant addressable cancer population PRECISION1 tumor-agnostic trial...